In Re Revance Therapeutics, Inc. Sec. Litig., No. 3:25-cv-0018-EJR

On January 3, 2025, the initial Class Action Complaint in this Action was filed in the United States District Court for the Middle District of Tennessee against Revance Therapeutics, Inc. and its directors and officers. The Complaint alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 based on materially false and misleading statements and omissions of material facts, in connection with the Company’s relationship with Teoxane SA and tender offer and merger transaction with Crown Laboratories, Inc.

E&C was appointed as Lead Counsel in the Action on March 20, 2025. Thereafter, on June 18, 2025, Lead Plaintiffs filed a Consolidated Complaint against all Defendants, alleging the Defendants violated, variously, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and Securities and Exchange Commission Rule 10b-5.

Defendants moved to dismiss the Consolidated Complaint on August 28, 2025. While the motion to dismiss was pending, the parties engaged the services of Jed D. Melnick, Esq., a nationally recognized mediator, to resolve the litigation. On January 22, 2026, the parties participated in an all-day mediation session with Mr. Melnick, and ultimately reached an agreement on February 1, 2026 to settle the Action for a total of $17 million.

The parties executed a Stipulation and Agreement of Settlement, Compromise, and Release, which was filed with the Court on March 20, 2026. The Court preliminarily approved the Settlement on April 10, 2026. After notice was disseminated to the Class, the Court granted final approval of the settlement on August 11, 2026.

Additional information concerning the settlement is available at: www.revancesecuritiessettlement.com

To view the relevant documents in this matter, please use the following links:

Back